
Novartis has announced that its product ribociclib (LEE011) has been granted fast-track review status as a first-line treatment of advanced …
Brenntag and dsm-firmenich expand biopharma vitamin partnership
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership

